Oscotec Inc.
Price Chart
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 1.42T KRW |
| Revenue | 101.55B KRW |
| Net Income | 57.17B KRW |
| Total Assets | 222.34B KRW |
| Net Assets | 182.53B KRW |
| Employees | 51 |
| Value | |
| P/E | 24.86x |
| P/B | 7.79x |
| P/S | 14.00x |
| EV/EBITDA | 28.26x |
| Profitability | |
| ROE | 31.32% |
| ROA | 25.71% |
| Op. Margin | 49.64% |
| Revenue Growth | 88.40% |
| Financial Health | |
| Debt Ratio | 121.81% |
| Total Debt | 16.63B KRW |
| Cash | 13.13B KRW |
| Current Ratio | 5.37x |
| Net Debt/EBITDA | 0.07x |
| Performance | |
| 1Y Return | 36.33% |
| 1M Return | -4.38% |
| From 52W High | -43.71% |
| 1Y MDD | -40.08% |
| Trading | |
| Volume | 426,526 shares |
| Foreign Own. | 12.43% |
| Per Share | |
| EPS | 1,452 KRW |
| BPS | 4,676 KRW |
Company Info
Oscotec, a new drug development biotechnology company established in 1998, specializes in synthetic new drug development, building a differentiated business model through the commercialization of its research products. Its targeted anticancer lung cancer treatment received approval as a first-line treatment from the Korean Ministry of Food and Drug Safety and the U.S. FDA. The company's autoimmune disease treatment has applied for additional clinical trials after completing global Phase 2a for ITP disease, while its next-generation anticancer drug received U.S. FDA Phase 1 Investigational New Drug (IND) approval, and its Alzheimer's disease treatment is undergoing Phase 1 clinical trials in the U.S. Oscotec is headquartered in Seongnam-si, Gyeonggi-do.